Finnhub•2026-04-24
Sonida Senior Living Announces First Quarter Earnings Release Date and Conference CallSNDA — Sonida Senior Living Inc
NYSE · Health Care · Health Care
$36.03+14.06%Market cap1.48B
- Latest Close
- $36.03
- 30-Day Move
- +14.1%
- Market Cap
- $1.5B
- Shares Outstanding
- 47,390,000
- P/B Ratio
- 11.95
- ROE
- -138.1%
Analyst consensus: Buy · 9 analysts
NYSE:SNDAHealth Care / Health CareDelayed public snapshot
Sonida Senior Living Inc
A read-only Alphactor snapshot forSonida Senior Living Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$36.03
30-Day Move
+14.1%
Market Cap
$1.5B
Shares Outstanding
47,390,000
P/B Ratio
11.95
ROE
-138.1%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$36.03
+14.1%last 90 delayed daily bars
Market cap$1.5B
90D High
$37.57
90D Low
$30.65
Avg Volume
305,558
What stands out
Net margin is -20.1%, useful for comparing SNDA against peers in Health Care.
SNDA is up 14.1% over the last 30 trading days shown on this page.
Latest operating income is $-13M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$25.89
Rule of 40
22.9%
Dark Pool Short %
25.0%
Fundamentals snapshot
Latest Close
$36.03
30-Day Move
+14.1%
Market Cap
$1.5B
Shares Outstanding
47,390,000
P/B Ratio
11.95
ROE
-138.1%
ROA
-8.4%
Operating Margin
-13.6%
Net Margin
-20.1%
Debt / Equity
13.46
Current Ratio
0.74
Latest Revenue
$381M
Financial statement snapshot
Revenue
$381M
Gross Profit
$336M
Operating Income
$-13M
Net Income
$-71M
Gross Margin
--
Net Margin
-2014.0%
Current Ratio
0.74
Debt / Equity
13.46
Valuation snapshot
Fair Value
$25.89
Upside / Downside
-28.1%
Signal
Overvalued
Implied Growth
30.1%
EV/Rev
$25.89
Growth Assumption
16.9%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$24M
Valuation spread
Current Price
$36.03
Composite Fair Value
$25.89
EV/Rev
$25.89
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Quality snapshot
Altman Z
0.67
Distress
Piotroski
3
Weak (0-3)
Cash Conversion
-0.34x
Rule of 40
22.9%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $238M | $-29M | $-54M | $-27M |
| 2023-12-31 | $255M | $-15M | $-21M | $-7M |
| 2024-12-31 | $304M | $-9M | $-2M | $-27M |
| 2025-12-31 | $381M | $-13M | $-71M | $-9M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-24
Baird Maintains Neutral on Sonida Senior Living, Raises Price Target to $37Finnhub•2026-04-23
Sonida Senior Living to Participate at Upcoming Investor Conferences in MaySeekingAlpha•2026-04-19
Janus Living: Valuation Seems To Have Priced In Near-Term UpsidesAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$100M
Sell Value
$0
Buys
5
Sells
0
Buy Value
$100M
Sell Value
$0
Buy/Sell Ratio
5.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | Detz Kevin | A | 12,723 | $0.00 |
| 2026-04-17 | Ribar Brandon | A | 23,023 | $0.00 |
| 2026-04-17 | Cober Timothy | A | 3,635 | $0.00 |
| 2026-04-17 | Levy Max | A | 8,482 | $0.00 |
| 2026-04-17 | Bailey Tabitha | A | 4,847 | $0.00 |
| 2026-04-05 | Detz Kevin | F | 4,461 | $32.18 |
| 2026-04-05 | Ribar Brandon | F | 7,010 | $32.18 |
| 2026-04-05 | Cober Timothy | F | 593 | $32.18 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 205,136 | 0.00% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 129,179 | 0.00% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 82,131 | 0.00% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 50,575 | 0.00% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 39,314 | 0.00% | 2026-02-28 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 26,916 | 0.00% | 2025-11-30 |
| iShares Trust-iShares Russell 2000 Growth ETF | 28,844 | 0.00% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 Value ETF | 17,672 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
$12M
-13.0%
BlackRock
Filed 2024-08-13
$7M
--
Geode Capital Management
Filed 2026-02-09
$5M
-3.9%
Renaissance Technologies
Filed 2026-02-12
$4M
+37.4%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.89
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
9
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.